If initiated early in disease, treatment may rarely reverse neurological sequelae and prevent further deterioration.[1]Shapiro MD, Feingold KR. Monogenic disorders causing hypobetalipoproteinemia. In: Feingold KR, Anawalt B, Boyce A, et al. eds. Endotext. South Dartmouth (MA): MDText.com, Inc.; 2000–2021.
https://www.ncbi.nlm.nih.gov/books/NBK326744
[2]Lee J, Hegele RA. Abetalipoproteinemia and homozygous hypobetalipoproteinemia: a framework for diagnosis and management. J Inherit Metab Dis. 2014 May;37(3):333-9.
http://www.ncbi.nlm.nih.gov/pubmed/24288038?tool=bestpractice.com